Amazon Enters Diagnostics Market: Dr Lal & Metropolis Stocks Slide

Amazon has officially stepped into India’s diagnostics market with the launch of Amazon Diagnostics—a move that sent shockwaves across the sector. Following the announcement, shares of top diagnostic firms Dr Lal PathLabs and Metropolis Healthcare fell up to 3% intraday, reflecting investor concern over heightened competition.

Amazon's new service offers at-home diagnostic testing, integrated into the Amazon Medical platform. Partnering with Orange Health Labs, the service covers six major cities—Delhi, Gurgaon, Noida, Mumbai, Bengaluru, and Hyderabad—across 450+ PIN codes. Customers can book 800+ tests, with sample collection in 60 minutes and same-day digital reports.

The move comes at a time when India’s diagnostics sector is booming, valued at $15 billion and growing at 8% annually. Notably, the organised segment is growing even faster at 12–14% CAGR, as more consumers shift to trusted digital-first services. Existing digital healthcare players—Tata 1mg, PharmEasy, Netmeds, and Apollo 24/7—are already jostling for market share.

Despite Amazon's reputation for aggressive pricing, the company has clarified that it won’t offer deep discounts. Instead, it plans to focus on market-level pricing, quality assurance, and seamless integration with the Amazon app, making convenience a key selling point.

Experts say the diagnostics segment is among the most profitable in the healthcare value chain. According to Tarun Sharma from 360 ONE Asset, Amazon’s entry adds pricing pressure for incumbents, even without discounts, because of its massive reach and tech advantage.

On the earnings front, Dr Lal PathLabs posted strong numbers in Q4 FY25, with an 81% YoY rise in net profit to ₹155 crore and a 10.5% revenue growth. Meanwhile, Metropolis Healthcare saw a 19% drop in profit to ₹29 crore, though revenue slightly increased to ₹345 crore.

Amazon’s foray could redefine how diagnostic services are delivered in India. While short-term earnings for incumbents look healthy, the long-term competitive threat is real. Companies like Dr Lal and Metropolis may need to upgrade digital capabilities, improve customer experience, and optimize pricing to stay relevant.